TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Study Details
Study Description
Brief Summary
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive multimodality treatment approach including surgery, radiation therapy and chemotherapy, overall survival remains poor. Novocure has shown that when properly tuned, very low intensity, intermediate frequency electric fields (TTFields) stunt the growth of tumor cells. The Optune system (NovoTTFTM Therapy) is a portable battery operated device, which produces TTFields within the human body by means of surface transducer arrays. The TTFields are applied to the patient by means of surface transducer arrays that are electrically insulated, so that resistively coupled electric currents are not delivered to the patient. Optune is currently FDA-approved as a single modality treatment for recurrent GBM when both surgical and radiotherapy options have been exhausted as well as combination with adjuvant temozolomide for newly diagnosed GBM.
This research study is being performed to determine whether or not TTFields combined with pulsed bevacizumab treatment increases overall survival in patients with bevacizumab-refractory GBM compared to historical controls treated with continuous bevacizumab alone or in combination with other chemotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Subjects who have evidence of bevacizumab-refractory GBM will be eligible to participate in this research study. Subjects will undergo 12 months of planned continuous treatment with TTFields followed by pulsed bevacizumab treatment when there is evidence of further progression per RANO, with the option of extending treatment up to a total of 24 months in patients who have not progressed and/or have adequate performance status at the 12 month mark. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle or until progression is noted again per RANO, whichever is later, at which time pulsed bevacizumab will be restarted as outlined above. The investigators believe that this approach will produce peaks and troughs in mitotic activities of glioma cells that render glioma cells more sensitive to the antimitotic activity of Optune during peak growth rates, thus lowering disease burden and increasing survival. In addition, the following will be performed: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Physical examination and quality of life (QoL) assessments will be performed bi-monthly. Brain MRI will be performed every 2 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Optune+Pulsed Bevacizumab The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. |
Drug: Bevacizumab
Bevacizumab will be given at 10mg/kg IV every 2 weeks.
Other Names:
Device: Optune
Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
Other Names:
Other: Brain MRI
Brain MRI will be done at screening and every 8 weeks.
Other Names:
Other: Quality of Life Questionnaires
The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall Survival [from date of starting Optune to date of death or censoring, whichever comes first, assessed up to 24 months]
Overall survival is defined as time interval from date of starting Optune to date of death or censoring whichever happens first.
Secondary Outcome Measures
- Karnofsky Performance Scale [Assessed up to 24 months]
The Karnofsky Performance Scale is rated from 0 - 100 with 0 = death and 100 = normal without complaints or evidence of disease. A higher score means the patient is better able to carry out daily activities. Patients are evaluable for assessment of QoL after completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period.
- Mini-Mental Status Exam [Assessed up to 24 months]
The Mini Mental State Examination (MMSE) it is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. The higher the score suggests less cognitive impairment. A score of 24-30 suggests no cognitive impairment. A score of 18-23 suggests mild cognitive impairment. A score of 0-17 suggests severe cognitive impairment. Patients are evaluable for assessment of QoL after completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period.
- Response Assessment in Neuro-Oncology (RANO) Measurement Form [Assessed up to 24 months]
The Response Assessment in Neuro-Oncology criteria were developed as an objective tool for radiologic assessment of treatment response in high-grade gliomas. Disease progression is defined as ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions (with the absolute increase of at least 1 dimension of at least 5 mm) compared with the smallest tumor measurement obtained either at baseline. Response assessment will be performed for patients completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed GBM, WHO grade IV. GBM variants and secondary GBM are allowed in any recurrence (including multiple) and have been treated with radiation and chemotherapy.
-
Unequivocal evidence of tumor progression during prior bevacizumab treatment per RANO criteria.
-
Patient is a candidate for, and agrees to proceed with additional bevacizumab treatment.
-
Male or female at least 22 years of age or older.
-
Karnofsky Performance Scale (KPS) ≥ 60%.
-
Planned treatment with TTFields therapy.
-
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of treatment.
-
Participants of childbearing/reproductive potential must use effective contraception.
-
Participants must be able to understand and willing to comply with protocol requirements as assessed by the investigator.
-
Signed informed consent according to institutional guidelines prior to registration.
Exclusion Criteria:
-
Inability to undergo brain MRI due to medical or personal reasons.
-
Currently receiving investigational agents that are intended as treatments of recurrent GBM.
-
Skull defect such as missing bone or bullet fragments.
-
Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, heart attack within the previous 12 months, stroke (except for TIA) within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Intracranial hemorrhage except for tumor associated micro hemorrhage.
-
Women who are pregnant or breastfeeding.
-
Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, vagus nerve stimulator, and other implanted electronic devices in the brain or the spinal cord.
-
Tumor located entirely in the infratentorium.
-
History of hypersensitivity to hydrogel.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Florida | Gainesville | Florida | United States | 32611 |
| 2 | Washington University | Saint Louis | Missouri | United States | 63110 |
Sponsors and Collaborators
- University of Florida
- NovoCure Ltd.
Investigators
- Principal Investigator: David D Tran, MD, PhD, University of Florida
Study Documents (Full-Text)
More Information
Publications
None provided.- IRB201600074
- OCR14874
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail | Ten patients were assessed for eligibility in this study. One subject did not meet eligibility. |
| Arm/Group Title | Optune+Pulsed Bevacizumab |
|---|---|
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. |
| Period Title: Overall Study | |
| STARTED | 9 |
| COMPLETED | 3 |
| NOT COMPLETED | 6 |
Baseline Characteristics
| Arm/Group Title | Optune+Pulsed Bevacizumab |
|---|---|
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. |
| Overall Participants | 9 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
8
88.9%
|
| >=65 years |
1
11.1%
|
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
54.7
(11.5)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
4
44.4%
|
| Male |
5
55.6%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |
| Hispanic or Latino |
0
0%
|
| Not Hispanic or Latino |
8
88.9%
|
| Unknown or Not Reported |
1
11.1%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
0
0%
|
| White |
8
88.9%
|
| More than one race |
0
0%
|
| Unknown or Not Reported |
1
11.1%
|
| Region of Enrollment (participants) [Number] | |
| United States |
9
100%
|
Outcome Measures
| Title | Overall Survival |
|---|---|
| Description | Overall survival is defined as time interval from date of starting Optune to date of death or censoring whichever happens first. |
| Time Frame | from date of starting Optune to date of death or censoring, whichever comes first, assessed up to 24 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| participants completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period |
| Arm/Group Title | Optune+Pulsed Bevacizumab |
|---|---|
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. |
| Measure Participants | 3 |
| Median (95% Confidence Interval) [months] |
7.4
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Optune+Pulsed Bevacizumab |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | We used one-sample log rank test to compare to historical control. | |
| Statistical Test of Hypothesis | p-Value | <0.001 |
| Comments | ||
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.3 | |
| Confidence Interval |
(2-Sided) % to |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Karnofsky Performance Scale |
|---|---|
| Description | The Karnofsky Performance Scale is rated from 0 - 100 with 0 = death and 100 = normal without complaints or evidence of disease. A higher score means the patient is better able to carry out daily activities. Patients are evaluable for assessment of QoL after completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period. |
| Time Frame | Assessed up to 24 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| participants completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period. |
| Arm/Group Title | Optune+Pulsed Bevacizumab |
|---|---|
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. |
| Measure Participants | 3 |
| Mean (Standard Deviation) [score on a scale] |
73.3
(5.8)
|
| Title | Mini-Mental Status Exam |
|---|---|
| Description | The Mini Mental State Examination (MMSE) it is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. The higher the score suggests less cognitive impairment. A score of 24-30 suggests no cognitive impairment. A score of 18-23 suggests mild cognitive impairment. A score of 0-17 suggests severe cognitive impairment. Patients are evaluable for assessment of QoL after completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period. |
| Time Frame | Assessed up to 24 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| participants completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period. |
| Arm/Group Title | Optune+Pulsed Bevacizumab |
|---|---|
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. |
| Measure Participants | 3 |
| Mean (Standard Deviation) [score on a scale] |
23.2
(5.1)
|
| Title | Response Assessment in Neuro-Oncology (RANO) Measurement Form |
|---|---|
| Description | The Response Assessment in Neuro-Oncology criteria were developed as an objective tool for radiologic assessment of treatment response in high-grade gliomas. Disease progression is defined as ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions (with the absolute increase of at least 1 dimension of at least 5 mm) compared with the smallest tumor measurement obtained either at baseline. Response assessment will be performed for patients completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period. |
| Time Frame | Assessed up to 24 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| after completing at least 8 weeks of treatment with the Optune device with compliance rate > 60% in at least one 4-week period. |
| Arm/Group Title | Optune+Pulsed Bevacizumab |
|---|---|
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. |
| Measure Participants | 3 |
| Progressive disease |
2
22.2%
|
| Stable disease |
1
11.1%
|
Adverse Events
| Time Frame | Adverse events were collected from start of treatment with Optune and continuously throughout study treatment (up to 24 months) plus an additional 30 days post study completion or withdrawal for up to 25 months. | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Optune+Pulsed Bevacizumab | |
| Arm/Group Description | The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI. Bevacizumab: Bevacizumab will be given at 10mg/kg IV every 2 weeks. Optune: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers. Brain MRI: Brain MRI will be done at screening and every 8 weeks. Quality of Life Questionnaires: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks. | |
All Cause Mortality |
||
| Optune+Pulsed Bevacizumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 6/9 (66.7%) | |
Serious Adverse Events |
||
| Optune+Pulsed Bevacizumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 4/9 (44.4%) | |
| Endocrine disorders | ||
| Hypothyroidism | 1/9 (11.1%) | 1 |
| General disorders | ||
| Non-cardiac chest pain | 1/9 (11.1%) | 1 |
| Fatigue | 1/9 (11.1%) | 1 |
| Metabolism and nutrition disorders | ||
| Hyperglycemia | 1/9 (11.1%) | 1 |
| Nervous system disorders | ||
| Headache | 1/9 (11.1%) | 1 |
| Seizure | 1/9 (11.1%) | 1 |
| Nervous system disorder | 1/9 (11.1%) | 1 |
| Vascular disorders | ||
| thromboembolic event | 1/9 (11.1%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| Optune+Pulsed Bevacizumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 6/9 (66.7%) | |
| Eye disorders | ||
| Blurred vision | 1/9 (11.1%) | 2 |
| Gastrointestinal disorders | ||
| Dyspepsia | 1/9 (11.1%) | 1 |
| Vomiting | 1/9 (11.1%) | 1 |
| General disorders | ||
| Fatigue | 3/9 (33.3%) | 3 |
| Edema | 2/9 (22.2%) | 2 |
| Pain | 1/9 (11.1%) | 1 |
| Injury, poisoning and procedural complications | ||
| Fall | 2/9 (22.2%) | 3 |
| Fracture | 1/9 (11.1%) | 1 |
| Investigations | ||
| Platelet count decreased | 1/9 (11.1%) | 2 |
| Musculoskeletal and connective tissue disorders | ||
| Muscle weakness | 1/9 (11.1%) | 4 |
| Extremity pain | 1/9 (11.1%) | 1 |
| Generalized muscle weakness | 1/9 (11.1%) | 1 |
| Myalgia | 1/9 (11.1%) | 1 |
| Nervous system disorders | ||
| Seizure | 5/9 (55.6%) | 8 |
| Memory impairment | 1/9 (11.1%) | 1 |
| Dysphasia | 2/9 (22.2%) | 2 |
| Dizziness | 1/9 (11.1%) | 1 |
| Dysarthria | 1/9 (11.1%) | 1 |
| Headache | 2/9 (22.2%) | 2 |
| Intracranial hemorrhage | 1/9 (11.1%) | 1 |
| Paresthesia | 1/9 (11.1%) | 1 |
| Nervous System Disorder | 2/9 (22.2%) | 3 |
| Psychiatric disorders | ||
| Confusion | 4/9 (44.4%) | 6 |
| Anxiety | 2/9 (22.2%) | 6 |
| Depression | 2/9 (22.2%) | 4 |
| Insomnia | 1/9 (11.1%) | 1 |
| Renal and urinary disorders | ||
| Proteinuria | 1/9 (11.1%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Epistaxis | 1/9 (11.1%) | 1 |
| Skin and subcutaneous tissue disorders | ||
| Pruritis | 1/9 (11.1%) | 1 |
| Skin disorder | 1/9 (11.1%) | 2 |
| Vascular disorders | ||
| Thromboembolic event | 1/9 (11.1%) | 2 |
| Hypertension | 1/9 (11.1%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | David Tran, MD, PhD |
|---|---|
| Organization | University of Florida |
| Phone | 352-273-9000 |
| david.tran@neurosurgery.ufl.edu |
- IRB201600074
- OCR14874